BACKGROUND: Age- and type-specific high-risk @entity1082 (hrHPV) incidence estimates in screen-eligible @entity1 are relevant from a public health perspective because they provide an indication of the effect of vaccination on the occurrence of screen-positives in HPV-based screening. However, limited data from @entity1 over 25 years of age are available. METHODS: In 24,105 hrHPV-negative @entity1 participating in Dutch (Population-Based Screening Study Amsterdam: POBASCAM) and Italian (New Technologies for @entity5 : NTCC) population-based randomized controlled screening trials the age- and type-specific distribution of incident @entity1083 detected at the next screening round was assessed. HPV types were grouped into vaccine (bivalent: @entity1799 /18; polyvalent @entity1799 /18/31/33/45/52/58) and nonvaccine types. RESULTS: The incidence of screen-detected hrHPV among @entity1 ages 29 to 56 years was 2.54% (95% confidence interval, 2.30-2.78) in POBASCAM and 2.77% (2.36-3.19) in NTCC. In both studies, the incidence of bivalent, polyvalent, and @entity281 decreased with age (P < 0.0001). Among @entity1 with @entity281 (s), vaccine-type positivity changed quadratically with age, in particular for the polyvalent vaccine (P values: POBASCAM: bivalent 0.264, polyvalent 0.038; NTCC bivalent 0.039, polyvalent 0.005). However, more than 20% and 50% of @entity1 with incident hrHPV were positive for bivalent and polyvalent vaccine types, respectively, in all ages in both studies. CONCLUSIONS: We observed decreasing age trends of hrHPV vaccine and nonvaccine type incidences and age-related differences in the vaccine-type positivity among @entity1 with @entity281 . Most importantly, @entity1083 continued to be detected in all ages and the contribution of vaccine types remained substantial. IMPACT: Our results indicate a considerable reduction of new @entity1083 in vaccinated cohorts, ensuing revision of screening guidelines. Cancer Epidemiol Biomarkers Prev; 1-8.   2014 AACR.

The Age Distribution of Type-Specific High-Risk XXXX Incidence in Two Population-Based Screening Trials.

@entity1 :: ('9606', 'Species') :: ['women'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Cervical Cancer'] @entity1083 :: ('MESH:D030361', 'Disease') :: ['hrHPV infections'] @entity281 :: ('MESH:D007239', 'Disease') :: ['incident infection', 'nonpolyvalent infections', 'incident infections'] @entity1799 :: ('333760', 'Species') :: ['HPV16'] @entity1082 :: ('10566', 'Species') :: ['human papillomavirus']
@entity1082 :: (10566,Species) :: ['Human Papillomavirus']
